Objectives: Clinical study results are still controversial about the timing of starting Everolimus (ERL) with and without calcineurin inhibitors (CNIs) after heart transplantation (HTx). We analyzed long-term data of the effect of ERL on renal function, the incidence of biopsy-proven acute cellular rejection (BPACR), and the incidence of cardiac allograft vasculopathy (CAV) in a real-life scenario.

Objectives: Various options of temporary mechanical circulatory support (tMCS) have shown to improve survival but only little data exist on bleeding complications during the time of tMCS using different devices. All forms of tMCS require anticoagulation and carry a risk of bleeding which has shown to be negatively associated with dismal outcome. The aim of this study was to compare bleeding complications under extracorporeal life support (ECLS) and Impella 5.0 (Abiomed, Danvas) therapy.

Cardiogenic shock carries a high risk for mortality despite various treatment options. Initial treatment using peripheral veno-arterial extracorporeal life support (ECLS) has shown to improve survival in patients in need of biventricular and lung failure, but is associated with bleeding, ischemic and infectious complications. The catheter based surgically implanted transaortic axial flow left ventricular assist device (LVAD) Impella 5.0 (Abiomed) seems to be a less invasive but equivalent hemodynamic alternative if right ventricular function allows switching from ECMO to Impella 5.0 to reduce peripheral ECLS associated complications.

Background: Extracorporeal life support (ECLS) has proved to improve survival of patients with refractory cardiogenic shock even with the need of resuscitation. Nevertheless weaning these patients from ECLS can be challenging and prolonged ECLS is associated with complications. In this study we hypothesized that Levosimendan improves the chances of successful weaning of ECLS and survival.

Objective: Extracorporeal life support (ECLS) is an established and recommended treatment modality in patients with acute carcinogenic shock. Safety and feasibility of this technique increased this treatment to out of hospital implantation and transportation. LV unloading in patients on ECLS has shown to increase survival and probability of successful weaning from short-term mechanical circulatory support (MCS). We here present our treatment algorithms and outcomes after ECLS implantation and transportation outside our own center.

Objective: Extracorporeal life support (ECLS) is an established and recommended treatment modality in patients with acute carcinogenic shock. Safety and feasibility of this technique increased this treatment to out of hospital implantation and transportation. However, in this very sick patient cohort further treatment remains challenging and complicated. We here present our treatment algorithms and describe the need of secondary interventions after arterial-venous ECLS implantation outside our own center.

The recently approved angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan has gained representation in the 2016 ACC/AHA/HFSA guideline update and the 2016 ESC guidelines. Wide experience with the substance in patients with terminal HF eligible for HTX is lacking. In an observational approach, we sought to determine to what extent the benefits of ARNI therapy apply in this context, whether the use is safe and whether it contributes to gaining clinical stability, and thus valuable time, in the process of HTX evaluation.